Mounjaro and Binge Eating Disorder: How Tirzepatide Affects Compulsive Eating

Mounjaro and binge eating disorder are increasingly discussed together as clinicians explore whether tirzepatide can help patients who struggle with compulsive overeating. Binge eating disorder (BED) is the most common eating disorder in the UK, yet it remains significantly underdiagnosed and undertreated. For many people living with both obesity and BED, standard weight-loss approaches fail because they do not address the neurological drivers behind binge episodes.

Tirzepatide, the active ingredient in Mounjaro, works on two key hormonal pathways: GLP-1 and GIP. Emerging research suggests these pathways influence not only appetite and blood sugar regulation but also the brain’s reward circuitry. This dual action is what makes Mounjaro particularly interesting for patients whose eating patterns go beyond simple overeating into the territory of a recognised psychiatric condition.

Current evidence suggests tirzepatide can reduce binge eating episodes by modulating both satiety signals and the brain’s reward response to food. However, Mounjaro is not licensed specifically for BED. The strongest clinical trial to date, the LIBERATE study (NCT06847399) at Johns Hopkins, is still recruiting. What we do know from completed research on GLP-1 receptor agonists is that these medications can significantly reduce binge frequency when combined with structured psychological support such as cognitive behavioural therapy (CBT). Mounjaro should never be used as a standalone treatment for binge eating disorder. A combined approach, guided by both a prescribing doctor and a psychologist or psychiatrist, offers the best outcomes.

Binge eating disorder is a formally recognised psychiatric condition, classified in both the DSM-5 and the ICD-11. It is characterised by recurrent episodes of eating large quantities of food in a short period, accompanied by a sense of loss of control. Unlike bulimia nervosa, BED does not involve compensatory behaviours such as purging or excessive exercise.

According to the National Institute for Health and Care Excellence (NICE), BED affects approximately 2 to 3 per cent of the adult population. In addition, the condition is significantly more common among people living with obesity. Studies suggest that between 20 and 30 per cent of individuals seeking medical weight-loss treatment meet the diagnostic criteria for BED.

Key features of BED include eating more rapidly than normal, eating until uncomfortably full, eating large amounts when not physically hungry, eating alone due to embarrassment, and feeling disgusted, depressed or guilty afterwards. These episodes typically occur at least once a week over a period of three months or more. Furthermore, the emotional distress associated with binge episodes often drives a cycle that makes the condition self-reinforcing.

The neurobiological basis of binge eating involves two interconnected systems: the homeostatic system that regulates hunger and satiety, and the hedonic or reward system that drives pleasure-based eating. In BED, the reward system is often dysregulated, meaning that food (particularly high-calorie, highly palatable food) triggers an exaggerated dopaminergic response in the brain’s mesolimbic pathway.

Tirzepatide acts on both systems simultaneously. As a GLP-1 receptor agonist, it stimulates pro-satiety POMC/CART neurons and inhibits orexigenic NPY/AgRP neurons in the hypothalamic arcuate nucleus. In practical terms, this means the sensation of fullness arrives sooner and lasts longer. A 2025 narrative review published in the International Journal of Molecular Sciences confirmed that GLP-1 receptor agonists dampen dopaminergic signalling in the mesolimbic reward pathway, thereby reducing the motivational and hedonic response to palatable food.

In particular, a phase 1 randomised trial published in Nature Medicine in 2025 demonstrated that tirzepatide altered ingestive behaviour in adults with overweight or obesity over a six-week period. Participants reported reduced food cravings, decreased preoccupation with food, and lower scores on validated eating-behaviour questionnaires. Many CutKilo patients describe a similar experience: the constant mental chatter about food, sometimes called food noise on Mounjaro, quietens significantly within the first few weeks of treatment.

The most rigorous clinical trial specifically investigating tirzepatide for BED is the LIBERATE study (NCT06847399), a phase 2 randomised controlled trial at Johns Hopkins University. The study compares tirzepatide against placebo and lisdexamfetamine dimesylate (the only medication currently licensed for BED in the United States) in 105 adults with both obesity and BED. All participants also receive guided self-help CBT. Recruitment began in September 2025, with primary completion expected in December 2027.

While LIBERATE has not yet reported results, a systematic review and meta-analysis published in PMC in early 2025 pooled data from existing GLP-1 receptor agonist studies and found clinically meaningful reductions in binge eating frequency. The review noted that GLP-1RA usage consistently reduced binge eating episodes and improved validated symptom scores across multiple trials. Moreover, these effects appeared to extend beyond simple appetite suppression to a genuine modulation of the compulsive eating behaviour itself.

A separate completed trial at Odense University Hospital (NCT06325670) examined GLP-1 receptor agonists in patients with type 2 diabetes and co-existing BED, with primary completion in April 2025. Consequently, we expect published results from this study to provide additional clarity on how tirzepatide-class medications perform in this specific patient group.

It is essential to understand that Mounjaro, while potentially helpful for reducing binge episodes, does not address the psychological and emotional triggers that drive binge eating. NICE guidelines recommend CBT-ED (eating disorder-specific cognitive behavioural therapy) as the first-line treatment for BED. Guided self-help based on CBT principles is also recommended as a less intensive alternative.

A combined approach offers the best outcomes for several reasons. First, tirzepatide can reduce the physiological drive to binge by modifying satiety signals and dampening the reward response. Second, CBT addresses the cognitive distortions, emotional triggers and behavioural patterns that sustain the binge cycle. Together, these two approaches work on different layers of the same problem.

At CutKilo, we take a doctor-led, supervised approach to Mounjaro treatment. If a patient discloses symptoms consistent with BED during their initial consultation or at any point during treatment, we recommend a parallel referral to a psychologist or psychiatrist with eating-disorder expertise. Similarly, patients who notice that their eating patterns shift from reduced appetite to episodic binges should report this promptly, as dose adjustments may be necessary.

If you recognise the symptoms of binge eating disorder in yourself, it is worth raising this with your prescribing doctor before or during Mounjaro treatment. Specifically, you should seek guidance if you regularly eat large amounts of food in a short period and feel unable to stop, if you eat in secret or feel intense shame afterwards, if you notice that your eating patterns follow emotional triggers such as stress, loneliness or boredom, or if previous diets have repeatedly failed because of episodes of uncontrolled eating.

Your doctor can screen for BED using validated tools such as the Binge Eating Scale (BES) or the Eating Disorder Examination Questionnaire (EDE-Q). If BED is confirmed, a treatment plan that combines Mounjaro with structured psychological support is likely to produce better and more sustainable results than either approach alone. Above all, an honest conversation with your clinician ensures your treatment plan addresses all aspects of your relationship with food.

Is Mounjaro licensed for binge eating disorder? No. Mounjaro (tirzepatide) is licensed in the UK for type 2 diabetes and, as Zepbound, for chronic weight management. It is not currently licensed for BED. However, the LIBERATE trial at Johns Hopkins is studying this specific use, and prescribing doctors may consider it off-label where clinically appropriate.

Can Mounjaro make binge eating worse? In most patients, tirzepatide reduces appetite and food preoccupation. However, some individuals may experience rebound hunger between doses or psychological distress related to rapid changes in eating patterns. If you notice an increase in binge episodes, contact your prescribing doctor promptly for a review.

Should I tell my doctor about BED before starting Mounjaro? Yes, absolutely. Disclosing any eating disorder history allows your doctor to tailor your treatment plan, adjust dose titration, and arrange appropriate psychological support from the outset.

What therapy works alongside Mounjaro for BED? CBT-ED (eating disorder-specific cognitive behavioural therapy) is the gold-standard psychological treatment for BED. Guided self-help based on CBT principles is also effective. Your GP can refer you through the NHS, or CutKilo can recommend private practitioners with eating-disorder expertise.

How quickly does Mounjaro reduce binge eating urges? Many patients report a noticeable reduction in food preoccupation and cravings within the first two to four weeks of treatment. The full effect on binge frequency may take longer to establish, particularly as doses are titrated upwards.

Tirzepatide offers genuine promise for patients living with both obesity and binge eating disorder. By targeting the brain’s reward pathways alongside its well-established metabolic effects, Mounjaro can reduce the frequency and intensity of binge episodes. Nevertheless, it works best as part of a combined strategy that includes structured psychological therapy. If you suspect you have BED, talk to your prescribing doctor openly. A treatment plan that addresses both the physiological and psychological drivers of compulsive eating gives you the strongest foundation for lasting change.